Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01358097 · ClinicalTrials.gov registry record

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

A clinical trial of Head and Neck Cancer and Oropharyngeal Cancer, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
33
Enrollment target
1
Study location

NCT01358097 is a study of Head and Neck Cancer and Oropharyngeal Cancer that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 33 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01358097, a study of Head and Neck Cancer and Oropharyngeal Cancer, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy. Current research demonstrates that several natural immune cells and molecules affect the way the body's immune system interacts with a cancerous growth. Some cancers may be related to infection with a virus, such as the Human Papilloma Virus (HPV). Studying the activity of the immune system in head and neck cancers, especially cancers related to HPV infections, can provide valuable information to better understand the body's interaction with cancer cells.

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai, Otolaryngology - Head and Neck Surgery - New York

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2010-10
Est. Completion 2013-09

What the Registry Record Tells You About NCT01358097

The ClinicalTrials.gov registry entry for NCT01358097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01358097 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01358097 about?

NCT01358097 is a clinical study titled "Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy". The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy. Current research demonstrates that several natural immune cells and molecules affect the way the body's immune system ...

What is the current status of trial NCT01358097?

This trial is currently completed. The enrollment target is 33 participants. The study started on 2010-10. Estimated completion is 2013-09.

What conditions does trial NCT01358097 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer.

Who is sponsoring clinical trial NCT01358097?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01358097 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.